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Abstract
Alzheimer’s disease (AD) is the most common form of dementia affecting 
millions of people worldwide and currently, the only possible treatment is the use 
of symptomatic drugs. Therefore, there is a need for new and disease-modifying 
approaches. Among the numbers of biological targets which are today explored in 
order to prevent or limit the progression of AD, the modulation of serotonin recep-
tors the subtype 4 and 6 receptors (5-HT4R and 5-HT6R) has received increasing 
attention and has become a promising target for improving cognition and limit the 
amyloid pathology through modulation of the neurotransmitter system. A large 
number of publications describing the development of ligands for these serotonin 
receptors have emerged, and their pharmaceutical potential is now quite evident. 
However, 5-HT4R and 5-HT6R functionality is much more complex than initially 
defined. This chapter describes recent advances in the understanding of this modu-
lation as well as the medicinal chemistry efforts towards development of selective 
5-HT4R or 5-HT6R ligands.
Keywords: serotonin pathways, Alzheimer’s, 5-HT4R and 5-HT6R modulators, 
structure–activity relationship
1. Introduction
Alzheimer’s disease (AD) is a devastating but poorly treated disease. Therefore, 
there is an urgent need for new and efficient treatment strategies, emphasized 
by recent statistics from WHO predicting that AD will become the second-most 
prevalent cause of death within 20 years.
Mounting evidence accumulated over the past years indicates that the neu-
rotransmitter serotonin plays a significant role in cognition and memory. The 
intimate anatomical and neurochemical association of the serotonergic system and 
brain areas affected in AD have inspired researchers to focus on this system as a 
major therapeutic drug target.
Based on the current knowledge of mechanisms involved in serotonin 
 regulation, we here provide structural insight into chemical compounds that have 
Serotonin and the CNS - New Developments in Pharmacology and Therapeutics
2
been developed for targeting of the serotonin receptors the subtype 4 and 6 recep-
tors (5-HT4R and 5-HT6R) processes as potential treatments in AD.
2. The serotonergic system in Alzheimer’s disease
Serotonin is a small molecule that functions both as a hormone in the periphery, 
and as neurotransmitter and neuromodulator in the central nervous system (CNS) 
[1]. In the CNS, it is produced by a small cluster of neurons located in the raphe 
nuclei of the midbrain. Through innervation of numerous brain regions, serotonin 
(5-hydroxytryptamine, 5-HT)  modulates various physiological functions including 
circadian rhythms, mood, sleep, appetite, and learning and memory. The areas of 
the brain involved in learning and memory show high concentrations of 5-HT1AR, 
5-HT4R, 5-HT6R and 5-HT7R, why modulation of these is of particular interest in 
for reversing the cognitive impairment associated with AD [2].
AD has been linked to a decrease of serotonergic neurons in the raphe nuclei, 
seemingly due to the accumulation of hyperphosphorylated Tau as well as deposits 
of amyloid beta in the projection sites of serotonergic neurons, causing retrograde 
degeneration of the neurons [3]. Furthermore, a significant decrease in the number 
of serotonin transporter (SERT) have also been reported [4]. Overall, this leads to 
a decrease in serotonin neurotransmission, suggesting that increasing serotonin 
level in the raphe nuclei can improve cognitive performance in AD patients. This is 
supported by studies showing that administration of selective serotonin reuptake 
inhibitors (SSRI) to mouse models of AD, reduced the production of toxic amyloid 
beta plaques [5, 6]. However, recent clinical trials concluded that treatment with 
amyloid beta lowering agents should be administered in the very early stages of the 
disease progression to have any impact on AD, limiting their use until better pre-
symptomatic AD diagnostics have been developed.
Several 5-HT receptors (5-HTR) have been shown to influence processing 
of the amyloid protein precursor (APP), including 5-HT2AR, 5-HT2CR, and 
5-HT4R [7, 8]. Among them, the 5-HT4R and 5-HT6R receptors have been of most 
interest. The 5-HT4R was identified as a most promising target, since activation 
of this receptor shift the equilibrium of APP cleavage towards formation of the 
soluble non-amyloidogenic form (sAPPα) fragment possessing neurotrophic and 
neuroprotective properties [7], while the 5-HT6R has caused much interest for 
potential roles in AD due to its modulatory effects on gamma-aminobytyric acid 
(GABA) and glutamate levels, [9] which facilitate the secondary release of other 
neurotransmitters including dopamine, noradrenaline and acetylcholine, all of 
which are compromised in AD. In addition, 5-HT6R are exclusively found in the 
CNS, indicating the possibility of selective CNS targeting to limit off-target toxic 
effects.
3. Serotonin subtype 4 receptor
Among the large family of 5-HTR, the 5-HT4R’s are postsynaptic receptors. 
Although widely expressed throughout the body, the highest density is observed 
in the brain (olfactory tubercles, basal ganglia, substantia nigra, superior collic-
uli, hippocampus, and cortex). These are all CNS structures that are extensively 
involved in cognitive functions, suggesting that the 5-HT4R could be a thera-
peutic target for improving memory performance and hereby slowing memory 
deficits, such as those that occur in AD [10]. Moreover, it has been shown that 
5-HT4R expression is reduced in AD patients. Furthermore, it has been shown 
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that activation of these receptors enhances the release of acetylcholine in the 
frontal cortex and hippocampus [11], increases long term potentiation in the 
hippocampus [12] and induces a rapid and sustained increase in basal firing of 
5-HT cells in the dorsal raphe nucleus [13, 14]. 5-HT4R activation also stimulates 
hippocampal expression of plasticity/learning-related proteins such as brain-
derived-neurotrophic-factor, AKT, CREB, as well as neurogenesis in the dentate 
gyrus [15].
In addition, and a major advantage of using 5-HT4R agonists in treatment of AD, 
is their ability to shift the equilibrium of APP processing pathway from production 
of the neurotoxic amyloid-beta-peptide towards formation of the sAPPα [16]. In 
contrast to amyloid-beta-peptide, the soluble form has putative neurotropic and 
neuroprotective properties, see Maillet et al. [17] for a review. The ability of 5-HT4R 
agonists to stimulate the amyloidogenic pathway leading to release of soluble form 
of APP has been demonstrated in various cell-based animal models [18].
In early years, 5-HT4R agonists attracted much attention as potential gastroin-
testinal drugs used in the therapy of functional bowel illnesses such as constipation, 
irritable bowel syndrome, gastroparesis, and gastroesophageal reflux disease [19]. 
The first generations of 5-HT4R agonists used in clinical medicine were Tegaserod 
(1), Cisapride (2) and Procalupride (3) (Figure 1A), which showed clinically 
effective in treatment of gastrointestinal motility disorders; however, adverse 
cardiovascular events have resulted in the restricted availability of these drugs [20]. 
Therefore, in order to develop clinically relevant 5-HT4R agonists, the ligands must 
be potent and highly selective, which is hampered by high similarity of subtype 
receptors. In 1998, the molecular structure and functional characterization of four 
splice variants of the human 5-HT4R were described [21] that differ in the carboxy 
terminal cytoplasmic domain while extracellular and transmembrane domains are 
absolutely conserved [22].
Figure 1. 
5-HT4 receptor ligands (A) first generations of 5-HT4R agonists used in clinical medicine, (B) partial 5-HT4R 
for treatment of AD that reached Phase 2 studies, (C) Overview of structures studied for development of 
partial 5-HT4R for treatment of AD.
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Another concern is the risk that prolonged or repeated exposure of the 
5-HT4R to an agonist, may lead to receptor desensitization. The 5-HT4Rs are 
G-protein-coupled receptors (GPCRs), which can be desensitized following 
activation by agonists [23]. Agonist-induced desensitization of GPCRs is less 
common for partial agonists than strong agonists and therefore, most focus has 
been given to developing highly selective partial 5-HT4R agonists for treatment 
of AD. In order to being therapeutic useful in treatment of AD, the compound 
must therefore fulfill several requirements. In addition to being a selective partial 
5-HT4R agonist, the target molecule must show good brain barrier penetration, 
which was also limited in the early generation agonists [24].
However, the potential for 5-HT4R partial agonists to offer clinical benefit for 
the treatment of AD has indeed been demonstrated. Data from a small Phase 2 
study in patients with mild to moderate AD with the selective partial 5-HT4R ago-
nist, PRX-03140 (4, EPIX Pharmaceuticals), [25] Figure 1B, showed a statistically 
significant improvement of cognitive processes after only two weeks of therapy 
[20]. Also, the partial agonist SL65.0155 (5, Sanofi-Aventis) reached phase II clini-
cal trial for the treatment of AD [26]. However, these were both later discarded due 
to serious off-target effects.
This has stimulated much research aiming at designing and developing more 
selective 5-HT4R partial agonists.
3.1 Pharmacophore of the 5-HT4R ligand
In accordance with the natural ligand, 5-HT (6), the general pharmacophore 
of 5-HT4R agonists consists of an aromatic core connected via a chemical spacer 
to a basic amino moiety [27] to introduce affinity, while an extra hydrogen-bond 
donor-acceptor function (e.g., phenol in 5-HT) is required for high affinity ligands 
[28]. Furthermore, it is accepted that voluminous substituents of the basic nitrogen 
interact with a hydrophobic pocket in the 5-HT4R ligand recognition site [29]. 
Based on this pharmacophore framework, a broad range of substances has been 
investigated, aiming at introducing selectivity.
Suitable aromatic systems [30] include 4- amino-5-chloro-2-methoxy benzoic 
acid, indole, imidazopyridines and N-alkyl benzimidazolodonone among others 
(see Figure 1C). Several basic amines with voluminous substituents such as piper-
izines [31], and piperidines [30] have been used.
3.2 Agonists of 5-HT4R
Over the last years, a broad range of structural varied 5-HT4R agonists have 
been developed, which all share the common structural features presented by the 
pharmacophore described above. Below we have grouped them into 4 main groups 
and discuss the structural features for each of these groups.
3.2.1 Group 1: benzisoxazole, oxindole and benzimidazolodonone core
Much research aiming at developing new 5-HT4R agonists has focused on 
compounds possessing a benzyl ring linked to a 5 membered heterocycle, analogous 
to the indole ring in the natural 5-HTR ligand.
Inspired from early generations of 5-HT4R agonists (1–3, Figure 1), Brodney 
and coworkers [32] synthesized and studied a diverse set of structural varied 
chemical libraries aiming at identifying excellent CNS active 5-HT4R agonists. To 
improve chances of identifying compounds with brain barrier penetration, struc-
tures were selected based on a number of criteria: (1) reduced number of hydrogen 
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donors (≤ 1), (2) low molecular weight (<400) and (3) weakly basic amine centers 
(pKa < 8,5) [33]. Based on these criteria, the benzisoxazole (7), oxindole (8) and 
benzimidazolodonone (9) was chosen as core structural templates.
For benzisoaxazoles (7), the studies showed that manipulation of molecu-
lar size and shape of the R1 and R2 groups (structure 7, Figure 2) provided 
means to modulate intrinsic properties and ADME (adsorption-distribution-
metabolism-excretion). Highly lipophilic compounds (R1 = n-butyl) resulted 
in high clearance from human liver and low passive permeability. Replacing the 
piperidine n-butyl group with hydroxyl-tetrahydropyran reduced the parti-
tion coefficient (ClogP), but analogue 10 still demonstrated high clearance. 
To further reduce ClogP, the isobytyl side chain was replaced with more polar 
groups. While the tertiary carbinol and tetrahydropyran analogues exhibited 
poor metabolic stability, the tetrahydrofyran 11 provided a potent partial agonist 
with low clearance.
Orjales and coworkers [33] provided a structure–activity-relationship (SAR) 
study of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxamide derivatives bearing a 
piperazine moiety (12a-h, Figure 3). Both, the influence of the 3-substituent of the 
benzimidazole ring, the 4-substituent of the piperazine moiety, and the alkylene 
spacer was studied and especially the substituent in the 3-position was found to be 
critical for 5-HT4R affinity. While compounds with ethyl (12a), and cyclopropyl 
(12b) substituents showed moderate to high affinity for the receptor, derivatives 
having smaller alkyl substituents (H: 12c, methyl: 12d, propyl: 12e) showed a 
significant drop in affinity. Also, introduction of large and bulky substituents 
(benzyl: 12f, butyl: 12g and phenylethyl: 12h) severely reduced the affinity for the 
5-HT4R. In addition to receptor affinity, also the 5-HT4R activity was dramatically 
influenced by substituents in the benzimidazolone 3-position. While ethyl- and 
cyclopropyl-functionalized derivatives (12a, 12b) showed moderate antagonistic 
activity, the isopropyl derivatives (12i and 13c) acted as partial agonists. The 
dramatic variation in the 5-HT4R pharmacological activity as a result of only small 
structural variations is in agreement with previous observations for benzoate 
derivatives [29].
A similar trend with benzimidazolone 5-HT4R ligands was reported by Langlois 
et al. [34] While the DAU-6215 ligand (13a) with no alkyl substituent on the 
nitrogen in the 3-position is in-active towards the 5-HT4R, the BIMU-1 (13b) and 
BIMU-8 (13c) compounds with ethyl and isopropyl substituents are potent 5-HT4R 
agonists [34, 35].
Figure 2. 
SAR studies of (A) benzisoxazole (7), oxindole (8) and benzimidazolodonone (9) core stuctures, (B) provided 
11 as a potent partial 5-HT4R agonist [32].
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3.2.2 Group 2: chloro-aniline core
The parent compound of this class is metoclopramide [36, 37] (14, Figure 4), 
a drug well-known for its gastric prokinetic activity. Furthermore, compounds 
having the chloro-aniline core is already well known to confer 5-HT4R agonist 
activity, for example in Cisapride (2) [38] and Mosapride (15) [39]. Therefore, it is 
not surprising that several derivatives of 4-amino-5-chloro-2-methoxybenzoic acids 
have been investigates as 5-HT4R agonist in AD research.
Russo et al. [40] synthesized and studied a library of structures based on the 
5-HT4R partial agonist, ML10302 (16, Figure 5) by introducing an amide group 
linked to the piperidine ring of ML10302 (16), Figure 5, hoping to introduce 
additional binding interactions. Displacements experiments with a 5-HT4R specific 
antagonist revealed that compounds in which the amide functionality was directly 
attached to the piperidine ring (17, n = 0) had weaker binding affinities compared 
to ML10302 (16). However, compounds where the amide moiety were attached to 
the piperidine ring through a methylene bridge, showed binding affinities that were 
globally better than ML10302 (16). Importantly, 4 compounds were identified that 
showed better functional properties than ML10302 (16) and induced up to 50% 
higher cyclic adenosinde monophosphate (cAMP) production. One compound (18) 
was further evaluated by in vivo biological tests, showing promising results for AD 
treatment.
RS67333 (19) [41] is a very affine 5-HT4R partial agonist, which also have high 
selectivity vs. other receptors. Its therapeutic relevance for treatment of AD is 
evident as it was shown to improve both object and place recognition in adult [42, 
43] and aged animals [44, 45]. On this basis, Dallemagne and coworkers synthe-
sized a series of analogues of RS6733 (19) [46], aiming at identifying a multitarget-
directed ligand (MTDL) having both 5HT4R agonist and acetylcholinesterase 
(AChE) inhibitor activities. Among them, the compound donecopride (20) was 
designed: The cyclohexyl moiety was introduced to be a compromise between the 
N-butyl group of RS67333 (19) and the bulky benzyl group of the potent AChE 
inhibitor, donepezil (21). Donecopride (20) showed outstanding in vitro activity 
and was able to potentiate both the 5-HT4R partial agonist activities as well as the 
Figure 3. 
Structures investigated in a SAR study of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxamide derivatives 
bearing a piperazine moiety [33].
Figure 4. 
Parent compounds of the chloro-aniline class of structures.
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inhibition of AChE, resulting in the alleviation of both amyloid aggregation and 
tau hyperphosphorylation, [47] which are known to be two major features in AD 
(Figures 6 and 7).
In 2019, Lanthier et al. [48] generated a MTDL targeting both activation of the 
5-HT4R while also bearing antioxidant activities; hereby being able to both control 
Ab protein accumulation and prevent toxicity of reactive oxygen species (ROS) in 
neuronal cells [48].
The chloro-aniline core connected via a chemical spacer to a basic piperidine 
ring (structure 22) was introduced as the 5-HT4R binding moiety of the MDLT. As 
replacement of the butyl chain of RS67333 (19) by diverse alkyl moieties has been 
shown to have limited impact on both the affinity and the pharmacological profile 
towards the 5-HT4R [46], the chemical moiety having antioxidant activities was 
introduced as substituent on the central piperidine ring. A variety of structures was 
investigated, varying in spacer between the two pharmacophores. Also, various 
Figure 5. 
Structures investigated in a SAR study of analogues of the 5-HT4R partial agonist, ML10302 [40].
Figure 6. 
A multitarget-directed ligand Donecopride (20) was developed to have both 5HT4R agonist and 
acetylcholinesterase inhibitor activities [46].
Figure 7. 
Compound 26 was developed by combining the 5-HT4R chloro-aniline pharmacophore (22) and structures 
(23–25) having antioxidant properties [48].
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chemical structures known to exhibit antioxidant activities were investigated, 
including polyphenol [49], hydroxycinnamic acid (23) [50], lipoic acid (24) [51, 
52], vanillin or isovanillin (25) [53, 54]. Hereby, Lanthier et al. were able to identify 
a potent 5-HT4R ligand (26) with promising antioxidant activity for future preclini-
cal tests.
A similar approach was investigated by Yahiaoui et al., who reported the 
design of the dual compound 27 with 5-HT4R agonist and 5-HT6R antago-
nist effects (Figure 8) [55]. The dual 5-HT4R/5-HT6R ligand was designed 
through modulation of the 5-HT4R partial agonist, RS67333 (19) by introduc-
ing a 5-HT6R  antagonist (28,29) pharmacophore (a positive ionizable atom, 
a hydrogen bond acceptor group, a hydrophobic site, and an aromatic-ring 
hydrophobic site) [56–60]. Yahiaoui et al. synthesized and tested a library of 
structures consisting of RS67333 (19) modulated with various arylsulfonyl 
groups (sulfonamides and sulfones) attached to the piperidine moiety through 
a variable number of methylene groups [61]. These studies resulted in iden-
tification of the compound 27 having nanomolar and submicromolar affini-
ties towards 5-HT4R and 5-HT6R, acting as a partial agonist and antagonist, 
respectively.
To further elaborate on these studies, Hatat et al. [61] designing an anti-
amnesic MTDL with balanced 5-HT4R agonist, 5-HT6R antagonist and AChE 
inhibitory activities. Starting from the dual MTDL 30 and the benzyl analog of 
Donecopride (35) [62], various analogues were designed and tested. However, 
counteracting requirements within the scaffold made the design difficult. While 
an unsubstituted benzyl group was the best substituent on the piperidine for 
affinity towards AChE and 5-HT4R, the 5-HT4R affinity appeared linked to 
substitution of the benzyl group. However, the analogue with a methyl group 
in the benzyl meta-position (32) showed balanced activities towards all three 
targets (Figure 9).
Figure 8. 
The dual 5-HT4R/5-HT6R ligand was designed through modulation of the 5-HT4R partial agonist, RS67333 by 
introduction of a 5-HT6R antagonist pharmacophore [55].
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3.2.3  Group 3: imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine, imidazo[4,5-b]
pyridine and imidazo[4,5-c]pyridine core
Compounds based on the imidazo[1,5-a]pyridine [63, 64] core were initially 
reported as dual mediators of 5-HT3R and 5-HT4R [65], see Figure 10 (33). 
However, work from Nirogi et al. provided an understanding of the substitution 
patterns on both the imidazo[1,5-a]pyridine ring and piperidine ring, allowing 
for development of 5-HT4R partial agonists based on this core [66]. Derivatives 
were designed as bioisosteric analogues of the potent 5-HT4R agonists BIMU-1 
and BIMU-8 (Figure 10, compounds 13b and 13c) [34] by replacing the benzimid-
azolone core with an imidazo[1,5-a] pyridine while preserving an alicyclic amine 
moiety, in accordance with the 5-HT4R pharmacophore (see section 3.1). Structural 
optimization was focused on modification of the alkyl substituent at the imid-
azopyridine ring, as well as the type of alicyclic amine. Also, a SAR iteration was 
carried out to understand the role of a methylene spacer between the amide group 
with the piperidine moiety, in addition to the effect of length and structure of the 
Figure 9. 
Antiamnesic MTDL (32) with balanced 5-HT4R agonist, 5-HT6R antagonist and AChE inhibitory 
activities [61].
Figure 10. 
SAR studies of imidazo[1,5-a]pyridine structures provided 34 as an efficient 5-HT4R partial agonist [66].
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N-alkyl/heteroalkyl chain. This process resulted in the discovery of a highly potent 
and selective partial 5-HT4R agonist 34 with pro-cognitive efficacy in rats and 
adequate ADME properties [66].
3.2.4 Group 4: quinoline core
Compounds containing the quinoline bicyclic aromatic core have attracted much 
attention in the design of 5-HT4R ligands [67–70]. To provide medicinal chemistry 
understanding of the quinoline 5-HT receptor ligands, Castriconi et al. [71] synthe-
sized and studied binding affinity of potential 5-HT4R agonists with reference to the 
5-HT4R ligands ML10302 (16) and PRX-03140 (4) by replacing the aromatic moi-
eties with 2-methoxyquinoline. Interestingly, the flexible quinoline derivatives 35, 36 
showed remarkable differences in 5-HT4R affinity. In fact, while the ester derivative 
35 showed a Ki value in the nanomolar range, the corresponding secondary amide 
36 was at least two orders of magnitude less active. This was ascribed to the chemi-
cal nature of the amid bond linking the side chain with the quinoline moiety in 36 
affecting the preferred conformation (Figure 11). To test this hypothesis, the flexible 
compounds 36 were transformed into the conformationally constrained derivatives 
37, 38 (Figure 11). This enhanced 5-HT4R affinity to the nanomolar range, suggest-
ing that the conformationally constrained derivatives 37, 38 represented the bioac-
tive conformation of ester 35, which cannot be populated by amide derivative 36 for 
steric reasons. The higher affinity of 38 compared to 37 suggests a secondary role of 
the second carbonyl group in the interaction with 5-HT4R binding site.
In later efforts, Cappelli and coworkers published a more comprehensive SAR 
study of receptor ligands with 2-methoxyquinoline as the aromatic system [72]. A 
series of piperidine containing functionalities were investigated, demonstrating 
N-butyl-4-piperidinylmethyl (also present in RS67333 (19), see Figure 12) to be 
a most promising basic moiety. Substituting the quinoline methoxy-substituent 
with a chloro- or cyclopropyl-substituent, did not have any significant effect on the 
activity (39a-d).
Figure 11. 
Quinoline 5-HT4 receptor ligands. Conformationally constrained derivatives 37, 38 showed improved affinity 
compared to the flexible compounds 35, 36 [71].
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4. Serotonin subtype 6 receptor
The 5-HT6R was discovered in 1993 by Monsma et al. [73–76]. These receptors are 
GPCRs, which are located postsynaptically to serotonergic neurons [77]. Since its iden-
tification, significant efforts have led to a better understanding of the biology of this 
receptor. The 5-HT6 receptors are present in regions of the brain regions responsible 
for learning and memory, making them of high interest in AD research. Furthermore, 
blockade of 5-HT6R function was shown to increase acetylcholine- and glutamate-
related neurotransmission, which enhances learning and memory [78, 79]. Evidence 
indicates that blockade of this receptor improve both cholinergic and glutamatergic 
system [79]. Furthermore, blockade of 5-HT6R alleviates memory deficits, such as age-
related decline in cholinergic or glutamatergic neurons, [79, 80]. Studies conducted by 
Kotańska et al. [74] revealed that antagonism of the 5-HT6R enhanced neuroplasticity, 
helped maintain neurite growth and provided a neuroprotective effect against amyloid 
beta neurotoxicity [81, 82].
This has led to a high interest in this receptor in treatment of the cognitive 
decline associated with AD [75, 78, 79, 83]. In addition, the receptor is exclusively 
expressed in the CNS, primarily in the striatal, hippocampal and cortical areas of 
the brain [75] and therefore, could potentially provide therapeutics with limited 
peripheral side-effects [80].
Among the first reported selective antagonists are Ro-04-6790 (40) reported in 
1998 [82, 84], SB-271046 (29) in 1999 [82, 85, 86] and SB-399885 (41) in 2002 [87] 
(see Figure 13) showed a 200-fold selectivity for the 5-HT6R. Although selective 
antagonists have been developed, no 5-HT6R antagonist has reached the pharmaco-
logical market to date. Thus, the search for new 5-HT6R agents is still of high focus 
in medicinal chemistry research. In this context, a better SAR understanding of the 
5-HT6R pharmacophore is needed.
Figure 12. 
A comprehensive SAR study of receptor ligands with 2-methoxyquinoline core structure provided 39a as an 
efficient 5-HT6R partial agonist [72].
Figure 13. 
Illustrations of the some of the first selective 5-HT6R antagonists; Ro-04-6790 (40), SB-399885 (41) and 
SB-271046 (29).
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4.1 Pharmacophore of the 5-HT6R ligand
From 1998 until today a fair number of studies have been conducted on 5-HT6R 
antagonists, which led to a good understanding of the pharmacophore. There are 
four main features responsible for interaction with the receptor: a polar positively 
ionizable (PI) group, a hydrogen bond acceptor (HBA), an aromatic area (AR) and 
a hydrophobic site (HYD) [75, 79] (see Figure 14).
In 2017, González-Vera and coworkers published [88] a SAR study regarding the 
hydrophobic moiety (HYD). In total 18 compounds were synthesized, all contain-
ing a sulfonamide as the HBA moiety. This study revealed that aromatic halogens in 
the HYD part of the structure increased affinity.
Based on this pharmacophore framework, a broad range of substances has been 
investigated as ligands for the 5-HT6R, aiming at introducing selectivity.
4.2 Antagonists for 5-HT6R
A comprehensive review was published by López-Rodríguez and colleagues in 
2014 [79], which discussed the structural key features of 5-HT6R antagonists. In 
this review, they grouped them into 4 overall groups of structures that had been 
investigated for antagonism of 5-HT6R (see Figure 15). They made some general 
conclusions, which are summarized in Figure 15.
For more details about specific compounds, please refer to [79]. This chapter 
will focus on studies made since 2014, while the reader is referred to the following 
excellent reviews [75, 79] for investigations before 2014.
A SAR study published by Zajdel et al. in 2016 [89] studied analogues of 
the natural substrate 5-HT (6) for the receptor. Aiming to increase affinity by 
constraining the ligand into its preferred conformation, a substituent (R1) was 
introduced to the tryptamine core, hoping to obtain a more constrained basic 
amine (Figure 16). Furthermore, an aryl arylsulfonyl moiety was introduced 
in the N1 position of the indole moiety. A total of 28 compounds were tested, 
which provided two compounds, 42 and 43, with both high affinity and 
selectivity for the 5-HT6R. The affinity data showed that R2 substituents were 
unfavored, while substituents in the indole C5 position improved properties 
Figure 14. 
Schematic illustration of the pharmacophore (stripped box) along with overlays with using the first selective 
















Representative examples from review by López-Rodríguez and colleagues [79]. The compound notation/numbering correlates with that of the review.
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(Figure 16). When reducing the double bond in compound 42 and 43, a slight 
decrease in affinity was observed, probably due to higher flexibility.
The two compounds were further tested for their functional activity in vitro and 
compared with reference compound SB-742457 (44). The compounds behaved as 
potent antagonist in a cAMP assay, while only displaying weak affinity for off-target 
receptors. Preliminary pharmacokinetic profiling of 43 showed good blood–brain-
barrier (BBB) penetration, improved recognition of novel objects in mice, in addi-
tion to a putative antidepressant activity in lower doses compared to the reference 
compound. Furthermore, 43 did not show any anxiolytic activity.
In 2019 Hogendorf et al. [90] published a comprehensive SAR study involv-
ing more than 50 compounds, all containing an aminoimidazole moiety as a new 
bioisoster of the classical PI amino-group. These were found to form strong hydro-
gen bonds with electronegative acceptors, such as carbonyls, in the enzyme active 
site. In total six different series were investigated, but only the two series that were 
found to be most important for activity are included in Figure 17.
Based on affinity, physiochemical properties (ClogP, pKa, topological polar 
surface area, water solubility, etc.), metabolic stability, mutagenic/toxicity and BBB 
permeation, compound 45, Figure 17, was chosen as the lead structure. The com-
pound showed high selectivity and displayed ability to reverse scopolamine-induced 
cognitive impairment. Crystallographic studies of the 2-aminoimidazole-based 
antagonists revealed that the high receptor affinity was reached due to a resonance 
driven conformational change [90] upon protonation of the imidazole fragment.
AD is more than just an imbalance in the cholinergic or glutamatergic systems 
and therefore, it was speculated whether better therapeutics could be achieved by 
using MTDLs affecting several neurotransmitter pathways [77]. In recent years, 
various MTDLs have been studied [81].
Marcinkowska et al. [81] designed MTDLs combining 5-HT6R antagonism, 
inhibitory effect against butyrylcholinesterase (BuChE) [91] and antioxidant prop-
erties [81], aiming at achieving both cognition-enhancing properties and neuropro-
tective activity. Both series were based on typical the 5-HT6R antagonist scaffold 
with a N-substituted 4-(piperazin-1-yl)-1H-indole core [79]. The indole 1-position 
was occupied with a benzyl group for series 1 and a 2-chloro benzene moiety for 
series 2 (marked with blue in Figure 18). The piperazine was N-substituted with 
an alkyl-phthalimide moiety with variation of the length of the alkyl chain (see 
Figure 18). The phthalimide group (marked with yellow in Figure 18) is known for 
interacting with the hydrophobic pocket in BuChE [92]. The indole moiety (marked 
with red in Figure 18), in addition to being important for 5-HT6R antagonism, had 
Figure 16. 
Summarizing the structures from the SAR, followed by two potential antagonists (42 and 43), along with 
reference compound SB-742457 (44). [89].
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antioxidant properties: Indoles are known for their ability to capture free radicals 
and protect biological systems against peroxidation [93]. From their screen they 
found that longer alkyl chains, connecting the phthalimide to the piperazine ring, 
decreased affinity for the 5-HT6R, while substituents on the benzyl group did not 
alter affinity significantly.
However, counteracting requirements within the scaffold complicated the 
design. From the BuChE inhibitor (BuChEI) screen they concluded that generally 
the unsubstituted benzyl analogues showed highest activity, with compound 46 
(R = H, n = 1) being the best inhibitor, while best 5-HT6R affinity was obtained 
with substrates having chloride in meta position on the benzyl moiety (47). Taking 
both targets into account, compound 48 (R = Cl, n = 1) showed the best overall 
properties, with good affinity for 5-HT6R, promising BuChE inhibitory effect 
and satisfying antioxidant properties. This SAR study demonstrated promise for 
MTDLs as AD therapeutics and inspired further research in the field.
Zajdel et al. recently [94] investigated MTDLs combining 5-HT6R inverse 
agonist activities and a monoamine oxidase B (MAO-B) inhibitory effect. The 
Figure 18. 
Schematic illustration of the model compound highlighting important feature for the MTDL. Compound 47 
was the best 5-HT6R antagonist from the study, compound 46 the best BuChE inhibitor and lead compound 48 
with the best overall results. [81].
Figure 17. 
SAR illustration covering two out of six series along with lead compound 45. [90].
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design included a 5-HT6R antagonist scaffold and fragments of either a reversible or 
an irreversible MAO-B inhibitor (see Figure 19) attached through an alkyl spacer of 
different lengths.
Their results indicate that the sulfone group was crucial for affinity to the 
5-HT6R, while non-substituted phenyl groups (R = H) seemed to result in the best 
5-HT6R binding. However, it is relevant to mention that no compounds contain-
ing the sulfone group together with the chloride-substituent were tested, making 
it difficult to make an overall conclusion. Among the 18 synthesized compounds, 
the very promising lead compound 49 was discovered. This compound displayed 
moderate metabolic stability, good artificial membrane permeability as well as 
good distribution in the brain. Furthermore, the compound showed glioprotective 
properties and fully reversed scopolamine-induced memory deficits.
In 2016 Grychowska et al. [83] published a study for a new core design based 
on a scaffold-hopping approach, with swapping of carbon and nitrogen atom in 
the indole ring [95], starting from the SSRI 6-nitroquipazine (50) to achieve the 
1H-pyrrolo [3,2-c] quinoline core (51). They afterwards studied alternating substi-
tution patterns on the arylsulfonyl fragment, which resulted in identification of 52, 
see Figure 20, as their lead structure for further studies. The SAR revealed that sub-
stituents in the meta-position of the phenyl were beneficial. However, it is difficult 
to make any general conclusions of this effect, as both electron-withdrawing and 
-donating substituents resulted in compounds with good affinity for the receptor. Of 
all the compounds tested, compounds containing a chloro-substituent were found 
to induce strong antagonistic properties. In general, the S enantiomers of the amino- 
pyrrolidine were more favored than the R enantiomers and compound 52 showed 
to be the best candidate with high selectivity for the 5-HT6R over the 5-HT1AR, 
5-HT2AR, 5-HT2CR, 5-HT2BR, 5-HT7R as well as dopamine (D2), adrenergic 
(alpha1A), histamine (H1), muscarinic acetylcholine (M1) receptors and SERT.
From a GPCR signaling assay it was determined that compound 52 behaved as 
neutral antagonist, whereas the reference SB-742457 (44) behaved as an inverse ago-
nist. In vivo studies demonstrated that both 52 and SB-742457 (44) have pro-cognitive 
properties, as they were able to reverse pharmacological-induced memory deficits in 
rats and improve recognition of novel objects. Additionally, 52 showed antidepressant 
properties. Compound 52 was later used as scaffold for development of a MTDL with 
both neuroprotective and precognitive activities (5-HT6R and dopamine subtype 3 
receptor (D3R) antagonism).
In an attempt to obtain the desired MTDL, Grychowska et al. [96] designed a 
series of 11 compounds combining structural elements of the 5-HT6R antagonist 52, 
(blue box in Figure 21) with structural elements of a D3R antagonist (Eticlopride 
[97] and Nafadotride [98]), red box in Figure 21. All compounds synthesized 
in the study showed moderate-to-high affinity for 5-HT6R; however, only four 
compounds showed acceptable affinity for D3R. An elongation in the length of the 
alkyl chain (R, Figure 21) provided a better binding to D3R, however, decreased 
the affinity for the 5-HT6R. A chloride-substituted phenyl (X = Cl) showed sig-
nificantly higher affinity for the 5-HT6R compared to the unsubstituted phenyl 
(X = H), in accordance with the previous mentioned importance of a halogen 
substituent (see section 4.1). Rewardingly, the S enantiomers were favored over 
the R enantiomers for both receptors. Based on all results, 53 showed overall good 
properties and its selectivity for the 5-HT6R compared to other receptors was stud-
ied. Fortunately, it did not bind to 5-HT1AR, 5-HT2AR or 5-HT7R and also showed 
a 10-fold selectivity over D2Rs. Furthermore, compound 53 proved to be a neutral 
antagonist, as it did not significantly affect the cAMP level. Its therapeutic potential 
was nicely demonstrated from animal studies, where both a neuroprotective effect 
and reversal of pharmacological-induced memory decline was observed.
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Structure 54 (see Figure 22) was identified through a drug discovery strategy based 
on a virtual screening platform [75, 99]. In total 45 compounds, all possessing the aryl-
sulfonamide, was held up against the knowledge of the binding pocket and 5-HT6R 
ligand pharmacophore, while also adding knowledge from the GPCR ligand database.
For several of the antagonists developed over the years, clinical trials seemed 
promising until the late studies. One example is the well-known non-sulfonyl 
Figure 20. 
SAR scaffold-hopping approach from SSRI (50) to 1H-pyrrolo[3,2-c] quinoline core (51) to lead compound 
52. [83].
Figure 21. 
Schematic illustration from MTDL SAR combining 5-HT6R antagonist core with selective D3R antagonist 
fragment, to give lead compound 53. [96].
Figure 19. 
Schematic illstration outlining the scope of the SAR study and potential MTDL compound 49. [94].
Serotonin and the CNS - New Developments in Pharmacology and Therapeutics
18
compound Idalopirdine or Lu AE58054 (55, Figure 22), discovered by Lilly. 
Idalopirdine was found to have high affinity for the 5-HT6R (>50-fold) compared to 
more than 70 targets studied [79] and reversed pharmacological-induced cognitive 
impairment. Lilly licensed the compound to Saegis for clinical development. Phase I 
was started in 2005 by Saegis and phase II in 2009 by Lundbeck (Lundbeck acquired 
Saegis in 2006) [100]. In phase II, Idalopirdine (55) was given to AD patients already 
receiving donepezil (21, an AChE inhibitor). It was found that Idalopirdine (55) 
provided an inhibitory effect on CYP206, which is involved in the metabolism of 
donepezil (21), therefore, it cannot be ruled out that the initial positive results origi-
nated from an increase in donepezil bioavailability [85]. Three Phase III studies with 
idalopirdine were initiated in 2013 involving patients with mild to moderate AD. 
Patients were treated with idalopirdine in combination with either donepezil (two 
of the studies; NCT02006641 and NCT01955161) or an unspecified AChE inhibitor 
(the third study; NCT02006654). Idalopirdine seemed to be highly tolerated with 
very few side effects. However, all three studies did not meet the necessary efficacy 
and Idalopirdine was therefore removed from the pipeline in 2017. (for more detail 
on the clinical trials the reader is referred to [101, 102]).
4.3 Neutral antagonists and inverse agonists for the 5-HT6R
An important feature of the 5-HT6R is its ability to exist in different confor-
mational states depending on the ligand bound, which can lead to initiation of 
different signal transduction pathways. The engagement of the 5-HT6R in several 
pathways has now been demonstrated. In addition to the canonical Gs adenylyl 
cyclase signaling pathway implicated in the control of neuronal migration [103], 
the 5-HT6R is also involved in pathways engaged in brain development of synaptic 
plasticity, more specifically the rapamycin [104] and cyclin-dependent kinase 
5 (Cdk5) signaling pathways [105]. Another relevant feature is the high level of 
constitutive activity of the 5-HT6R. The 5-HT6R has different pathways that can 
be activated upon different antagonistic and agonistic approaches, and the above-
mentioned problems during clinical trials, stimulated interest for investigating 
other mechanistic approaches against the receptor.
It is worth having in mind that Cdk5-dependent neurite growth has been found 
to involve the 5-HT6Rs [105] and being agonist dependent. An inverse agonist of 
this signaling system, like SB-258585 (56, Figure 23) prevents neurite growth, 
neuronal migration and dendritic spine morphogenesis [96, 105]. For this purpose, 
both neutral antagonists and inverse agonists have been investigated.
Utilizing a scaffold-hopping approach based on swapping one carbon with 
a nitrogen atom in the indole ring, Vanda et al. [95] synthesized 33 compounds 
varying in both the position of the nitrogen, alkyl-substituents on the C2 position 
(R-group, Figure 23) and substituents on the benzyl group and based on biological 
Figure 22. 
(left) Compound 54 obtained from a virtual screening platform [75, 99]. (right) Idalopirdine/LuAE58054 
(55) [100].
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testing, they made some general conclusions. Localization of the nitrogen was 
crucial for 5-HT6R affinity and compounds with the imidazole[4,5-b]pyridine 
fragment were in general the best binders. Elongation of the benzyl to a phenethyl 
group decreased affinity. Furthermore, while bulky and aromatic substituents were 
not tolerated in the C2 position, small alkyl substituents was in general accepted, 
with the ethyl-group being the most favored. Furthermore, substituents in the ben-
zyl 3-position were generally preferred, while substituents in the 2- and 4-position 
lowered affinity compared to the non-substituted analogue. The studies resulted in 
identification of compound 57 as a new and potent 5-HT6R partial inverse agonist 
at the Gs signaling pathway, while being a neutral antagonist in the Cdk5 pathway.
4.4 Agonists for the 5-HT6R
Interestingly, it has been suggested that not only 5-HT6R antagonists but also 
5-HT6R agonists may have pro-cognitive activities [107]. The 5-HT6R agonist WAY-
181187 (58) was shown to enhance GABA concentrations, which may potentially 
Figure 23. 
Illustration of conducted SAR study adapted from [106] and the obtained lead compound (57), along with 
compound 56.
Figure 24. 
5-HT6R agonists; WAY-181187 (58) [108, 109], WAY-208466 (59) [109], EMDT (60) [110], EMD386088  
(61) [111], E-6801 (62) [112], R-13c (63) [113], ST1936 (64) [114].
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have a positive effect on the neuronal plasticity [76], likewise enhancing cholinergic 
and glutamatergic mechanisms [80], indicating that both activation and inhibi-
tion of this receptor evoke similar responses. Although, the mechanism behind 
these paradoxical similar effects of 5-HT6R agonists and antagonists is not fully 
understood, it has been suggested that they could be acting on receptors located on 
distinct neuronal populations. Further discussing of these paradoxical effects can 
be found in [80], where also other possible explanations are presented.
Several 5-HT6R agonists have been identified, some of them are summarized in 
Figure 24 [80].
The effectiveness of the antagonist vs. the agonist approach is further discussed 
in reviews by Meneses et al. [115] and Fone [80].
5. Conclusion
Alzheimer’s disease is increasingly being recognized as one of the most challeng-
ing medical and social challenging health concerns in older people. To date, only 
treatments offering symptomatic relief to patients exist for this disease, limiting 
benefit to patients. As there is no curable medical treatment available, much effort 
has been focusing on identifying novel potential targets for drug development. The 
rich involvement of serotonin (5-HT) in both cognition and memory; some of the 
most symptomatic areas being affected in AD, has directed current drug discovery 
programs to focus on this system as a major therapeutic drug target.
Thus, serotonin receptor modulators offer an attractive option for a future 
treatment of AD patients and modulation of 5-HT4R has indeed demonstrated to 
improve neurotransmission and enhance the release of acetylcholine resulting in 
the memory formation. Furthermore, in various cell based and animal models, 
partial 5-HT4R agonists were demonstrated to promote the release of sAPPα and 
block the release of amyloid beta peptide. Remarkably, 5-HT4R agonists were also 
reported to induce neurogenesis in hippocampus as well as enteric system through 
the activation of cyclic AMP response element binding protein in rodents.
During the past 20 years, also the 5-HT6R has received increasing attention 
and is now a promising target for improving cognition. However, 5-HT6R func-
tionality is much more complex. Several studies with structurally different com-
pounds have shown that not only antagonists but also 5-HT6R agonists improve 
learning and memory in animal models. This paradoxical effect may explain why 
several compounds that reached phase III clinical trials failed to replicate the posi-
tive impact on cognition [76, 94]. Therefore, even though preclinical and clinical 
trials show that the 5-HT6R is a promising target for treatment of neurodegenera-
tive diseases such as AD, there is an urgent need for a better understanding of 
the pathways involved in modulation of the receptor. However, there is hope that 
with the recent advances in molecular biological techniques, including improved 
cloning and sequencing methods, strategies for the development of in silico 
GPCR models, will advance our understanding of the molecular mechanisms 
underlying the impact of serotoninergic signaling in AD to provide beneficial 
treatments for AD.
Taken together, 5-HT4R and 5-HT6R modulators address all major facets of AD. 
However, although important progress has been made with developing relevant 
modulators to improve both cognition and memory, crucial challenges still need to 
be overcome before a promising cure to AD has been found. Most importantly, an 
in depth understanding of the pathways involved in modulation of the serotonin 
receptors is urgently needed. Also, to limit side-effects the identification of CNS 
specific molecules is crucial.
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ADME absorption, distribution, metabolism, and excretion
alpha1A adrenergic




cAMP cyclic adenosinde monophosphate
Cdk5 cyclin dependent kinase 5
ClogP calculated logarithm of octanol/water partition coefficient
CNS central nervous system
D2 dopamine
D3R dopamine subtype 3 receptor
GABA gamma-aminobytyric acid
GPCR G protein-coupled receptor
H1 histamine
HBA hydrogen bond acceptor
HYD hydrophobic site
M1 muscarinic acetylcholine
MAO-B monoamine oxidase B
MTDL multitarget-directed ligands
PI positively ionizable
ROS reactive oxygen species
sAPPα soluble non-amyloidogenic form
SAR structure–activity relationship
SERT serotonin transporter
SSRI selective serotonin reuptake inhibitors
5-HT 5-hydroxytryptamine
5-HT4R 5-hydroxytryptamine receptor 4
5-HT6R 5-hydroxytryptamine receptor 6
5-HTR 5-hydroxytryptamine receptor
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